Latest Growth Strategy News

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, beating guidance and setting a solid foundation for FY26 with continued organic growth and improved profitability.

Alcidion Group Limited has reported a transformative FY25 with record earnings, a major NHS contract win, and a robust outlook for FY26. The company’s healthcare technology platform is gaining traction across the UK and Australia, setting the stage for accelerated growth.

Centuria Industrial REIT (ASX – CIP) has announced a $300 million exchangeable notes offering due 2030, alongside a concurrent repurchase of existing notes, aiming to lower debt costs and extend maturity. The move underscores CIP’s strategic capital management amid a complex market environment.

Macquarie Technology Group reported modest revenue and profit growth for FY25, underpinned by a new $450 million undrawn debt facility aimed at expanding its data centre portfolio. The company’s strategic investments include the on-time construction of IC3 SuperWest and a $240 million option to acquire land for a new Sydney campus.

Shriro Holdings reported a 5.5% beat on EBITDA guidance despite a 13.6% revenue decline driven by strategic shifts in its importer model and distributor consolidation. The company signals optimism for FY26 with new product launches and a capital-light growth strategy.

Shriro Holdings reported a 5.5% rise in EBITDA for FY25 despite a 13.6% revenue dip, driven by strategic shifts including a new US distributor and innovative BBQ product launches.

Nido Education Limited reported an 8% rise in Service EBITDA to $12.8 million for the first half of 2025, maintaining steady operational performance despite sector-wide occupancy challenges. The company declared a fully franked interim dividend of 1.5 cents per share, underscoring confidence in its growth strategy.

GenusPlus Group Ltd has reported a robust 36% increase in revenue and an 84% surge in net profit for FY2025, driven by strategic acquisitions and growth in the renewable energy sector. The company also declared a higher fully franked dividend, reflecting confidence in its expanding infrastructure footprint.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Infragreen Group Ltd has reported a strong FY25 performance, exceeding its prospectus forecasts post-IPO and advancing its footprint in clean energy and waste recovery sectors. The company’s strategic acquisitions and organic growth set the stage for continued momentum into FY26.

Infragreen Group Limited has reported a robust FY25 performance, with pro forma revenue and EBITDA significantly exceeding forecasts, supported by a successful $40 million IPO.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.